Patents by Inventor Matthew Lindon

Matthew Lindon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2,3-DISUBSTITUTED 1-ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS
    Publication number: 20230040299
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Application
    Filed: August 25, 2022
    Publication date: February 9, 2023
    Inventors: Dominique Amans, Stephen John Atkinson, Lee Andrew Harrison, David Jonathan Hirst, Robert Peter Law, Matthew Lindon, Alexander Preston, Jonathan Thomas Seal, Christopher Roland Wellaway
  • 2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors
    Patent number: 11478478
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Grant
    Filed: January 7, 2020
    Date of Patent: October 25, 2022
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: Dominique Amans, Stephen John Atkinson, Lee Andrew Harrison, David Jonathan Hirst, Robert Peter Law, Matthew Lindon, Alexander Preston, Jonathan Thomas Seal, Christopher Roland Wellaway
  • 2,3-DISUBSTITUTED 1-ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS
    Publication number: 20210046073
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Application
    Filed: January 7, 2020
    Publication date: February 18, 2021
    Inventors: Dominique Amans, Stephen John Atkinson, Lee Andrew Harrison, David Jonathan Hirst, Robert Peter Law, Matthew Lindon, Alexander Preston, Jonathan Thomas Seal, Christopher Roland Wellaway
  • 2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors
    Patent number: 10583139
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: March 10, 2020
    Inventors: Dominique Amans, Stephen John Atkinson, Lee Andrew Harrison, David Jonathan Hirst, Robert Peter Law, Matthew Lindon, Alexander Preston, Jonathan Thomas Seal, Christopher Roland Wellaway
  • 2,3-DISUBSTITUTED 1 -ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS
    Publication number: 20180303831
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Application
    Filed: June 25, 2018
    Publication date: October 25, 2018
    Inventors: Dominique AMANS, Stephen John ATKINSON, Lee Andrew HARRISON, David Jonathan HIRST, Robert Peter LAW, Matthew LINDON, Alexander PRESTON, Jonathan Thomas SEAL, Christopher Roland WELLAWAY
  • 2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors
    Patent number: 10034881
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: July 31, 2018
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Dominique Amans, Stephen John Atkinson, Lee Andrew Harrison, David Jonathan Hirst, Robert Peter Law, Matthew Lindon, Alexander Preston, Jonathan Thomas Seal, Christopher Roland Wellaway
  • 2,3-DISUBSTITUTED 1 -ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS
    Publication number: 20170189401
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Application
    Filed: March 23, 2017
    Publication date: July 6, 2017
    Inventors: Dominique AMANS, Stephen John ATKINSON, Lee Andrew HARRISON, David Jonathan HIRST, Robert Peter LAW, Matthew LINDON, Alexander PRESTON, Jonathan Thomas SEAL, Christopher Roland WELLAWAY
  • 2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors
    Patent number: 9637456
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: May 2, 2017
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Dominique Amans, Stephen John Atkinson, Lee Andrew Harrison, David Jonathan Hirst, Robert Peter Law, Matthew Lindon, Alexander Preston, Jonathan Thomas Seal, Christopher Roland Wellaway
  • 2,3-DISUBSTITUTED 1 -ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS
    Publication number: 20160016908
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Application
    Filed: March 12, 2014
    Publication date: January 21, 2016
    Applicant: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Dominique AMANS, Stephen John ATKINSON, Lee Andrew HARRISON, David Jonathan HIRST, Robert Peter LAW, Matthew LINDON, Alexander PRESTON, Jonathan Thomas SEAL, Christopher Roland WELLAWAY
  • Substituted piperazines,(1,4) diaszepines, and 2,5-diazabicyclo (2.2.1)iieptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists
    Publication number: 20060025404
    Abstract: The present invention relates to novel piperazine and azepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurodegenerative disorders including Alzheimer's disease.
    Type: Application
    Filed: October 14, 2003
    Publication date: February 2, 2006
    Inventors: Rachel Ancliff, Colin Eldred, Yvonne Fogden, Ashley Hancock, Thomas Heightman, Heather Hobbs, Simon Hodgson, Matthew Lindon, David Wilson
  • Compounds
    Publication number: 20060019964
    Abstract: 1-{4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl}-4-{[4-(methylsulfonyl)phenyl]carbonyl}piperazine or a derivative thereof.
    Type: Application
    Filed: April 22, 2005
    Publication date: January 26, 2006
    Inventors: Ranchael Ancliff, Colin Eldred, Yvonne Fogden, Ashley Hancock, Thomas Heightman, Heather Hobbs, Simon Hodgson, Matthew Lindon, David Wilson
  • Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain
    Publication number: 20050107388
    Abstract: The present invention provides compounds of formula (I); pharmaceutically acceptable salts and N-oxides thereof in which A, B, D and E are C or N with the proviso that one or more are N, R1, R2, R3, R4, R5 and R6 are simple substituents, n is 0-3 and y is an aryl, heteroaryl, carbocyclyl or fused-carbocyclyl group; as VR-1 antagonists for treating conditions or diseases in which pain and/or inflammation predominates; the use of the same for manufacturing medicaments, pharmaceutical compositions comprising them and methods of treatment utilising them.
    Type: Application
    Filed: March 21, 2003
    Publication date: May 19, 2005
    Inventors: Rebecca Brown, Victoria Doughty, Gregory Hollingworth, A. Jones, Matthew Lindon, Christopher Moyes, Lauren Rogers